CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement 3-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis Intravascular Ultrasound Parameters Associated With Stent Thrombosis After Drug-Eluting Stent Deployment Combined use of OCT and IVUS in spontaneous coronary artery dissection Transcatheter Mitral Valve Replacement in Patients with Heart Failure and Secondary Mitral Regurgitation: From COAPT Trial Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis 1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation: Results From the TriValve Registry

Original ResearchVolume 74, Issue 13 Supplement, October 2019

JOURNAL:J Am Coll Cardiol. Article Link

Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Subgroup Analysis From ULTIMATE Trial

JJ Zhang, XF Gao, the ULTIMATE Investigators. Keywords: IVUS guidance vs angiography guidance; TVF; CKD

ABSTRACT


BACKGROUND - Patients with chronic kidney disease (CKD) present more frequently with complex and extensive lesions, and intravascular ultrasound (IVUS)–guided drug-eluting stent (DES) implantation is associated with improved clinical outcomes in complex lesions. However, it still remains controversial that routine IVUS guidance could be beneficial to CKD patients.


METHODS - This study aimed to investigate the impact of IVUS- or angiography-guided DES implantation on patients with CKD based on the database from the ULTIMATE trial.


RESULTS - Estimated glomerular filtration rate (eGFR) was available in 1,443 patients, with mean eGFR 81.41 ± 28.92 ml/min/1.73 m2, of whom 723 were in the IVUS guidance group and 720 in the angiography guidance group. Finally, CKD was present in 349 (24.2%) patients. At 12 months, the target vessel failure (TVF) in the CKD group was 7.2%, significantly higher than 3.2% in the no CKD group (hazard ratio [HR]: 2.30; 95% CI: 1.38 to 3.84; p = 0.001), mainly driven by increased risk of cardiac death (2.9% vs. 0.5%; p < 0.001) in CKD patients. Moreover, there were 25 TVFs in CKD patients, with 7 (3.9%) in the IVUS group and 18 (10.7%) in the angiography group (HR: 0.35; 95% CI: 0.15 to 0.84; p = 0.01) (Figure), while 35 TVFs occurred in patients without CKD, with 14 (2.6%) in the IVUS group and 21 (3.8%) in the angiography group (HR: 0.67; 95% CI: 0.34 to 1.32; p = 0.25; p for interaction = 0.24). The reduced risk of TVF in the IVUS group for CKD patients was mainly driven by the lower risk of TVMI (0.6% vs. 3.6%; borderline p = 0.05) and TVR (1.1% vs. 4.7; p = 0.04).


CONCLUSION - The present study demonstrated that CKD patients undergoing DES implantation had a higher risk of TVF during 12 months of follow-up. More importantly, the risk of TVF in CKD patients could be significantly decreased through IVUS guidance compared with angiography guidance.